Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference
Insmed, a biopharmaceutical company focused on rare and serious diseases, will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insmed, a biopharmaceutical company focused on rare and serious diseases, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 7:30 a.m. ET. This event will be available for live streaming and archived for 30 days. Insmed's mission is to improve patient lives through innovative therapies, including its first commercial product for a lung disease and a pipeline targeting unmet medical needs in inflammatory diseases and rare pulmonary disorders. More information can be found on www.insmed.com.
Details
News Market Reaction – INSM
The recorded move for INSM in the trading session of this news was +0.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Jan. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 7:30 a.m. ET.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of each live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States and the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301197064.html
SOURCE Insmed Incorporated
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.